|
May 23
|
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
|
|
May 23
|
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
|
|
May 22
|
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
|
|
May 22
|
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
|
|
May 22
|
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi
|
|
May 22
|
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
|
|
May 22
|
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
|
|
May 22
|
Sanofi gains experimental Alzheimer’s drug through Vigil buyout
|
|
May 22
|
Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition
|
|
May 22
|
Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal
|
|
May 22
|
Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play
|
|
May 21
|
Sanofi to Buy Vigil Neuroscience for About $470 Million
|
|
May 21
|
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
|
|
Jan 23
|
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
|
|
Aug 13
|
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
|
|
Aug 1
|
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
|
|
Jul 30
|
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
|
|
Jul 24
|
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
|
|
Jul 24
|
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
|
|
Jun 27
|
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
|